Otrexup
Drug - Otrexup™ (methotrexate for subcutaneous injection) [Antares Pharma, Inc.]
June 2014
Therapeutic area - Rheumatoid arthritis; polyarticular juvenile idiopathic arthritis; psoriasis
Approval criteria
Approval will only be granted for diagnoses of rheumatoid arthritis; polyarticular juvenile idiopathic arthritis (pJIA); severe, disabling psoriasis.
Rheumatoid Arthritis, pJIA approval criteria
- Patient must have a diagnosis of rheumatoid arthritis or pJIA AND
- Patient cannot swallow a tablet whole AND
- Patient is not taking any other tablet whole by mouth OR
- Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection
Psoriasis approval criteria
- Patient must have a diagnosis of psoriasis AND
- Patient has tried and failed topical therapy AND
- Patient cannot swallow a tablet whole AND
- Patient is not taking any other tablet whole by mouth OR
- Prescriber provides a compelling reason why patient cannot take generically available methotrexate by mouth or injection
Quantity limit
1.6 ml per 34 days (all strengths)
Background information
Otrexup™ will only be authorized for approved FDA indications.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411